Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration approved Spiriva Respimat (tiotropium bromide) inhalation spray as a treatment for bronchospasm associated with chronic obstructive pulmonary disease.
In celebration of the 30th anniversary of the enactment of the Drug Price Competition and Patent Term Restoration Act, also known as the “Hatch-Waxman” Act, the National Association of Chain Drug Stores issued a statement to reflect on the evolution of providing patient access to generic medications and noted that it is looking forward to further progress in the years ahead.
In honor of the 30th anniversary of the Drug Price Competition and Patent Term Restoration Act — more commonly known as the Hatch Waxman Act — which enabled manufacturers to bring generic versions of pharmaceuticals to market more easily, GPHA president Ralph Neas issued a statement.
A bill has been introduced that lawmakers say would “close federal loopholes” and increase consumer access to generic drugs while boosting market competition.
The Food and Drug Administration on Thursday approved Trulicity (dulaglutide), a once-a-week injection to improve blood-sugar levels in adults with Type 2 diabetes.
The National Association of Chain Drug Stores has offered its support for new legislation — S. 2862, the Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014 — which calls for a collaborative, coordinated approach to curbing prescription drug abuse and safeguarding patients.
The National Association of Chain Drug Stores submitted a statement urging transparency, collaboration and prioritization in working with pharmacy and other healthcare stakeholders to help protect patient access and fight prescription drug abuse and diversion.
More than 50 Washington, D.C.-area pharmacists and student pharmacists administered flu shots and performed free health screenings on Capitol Hill on Wednesday to demonstrate the value of pharmacist-provided patient care services.
The Generic Pharmaceutical Association on Thursday provided input on the Generic Drug User Fee Act process before the Food and Drug Administration.
Mission Pharmacal on Tuesday participated in a White House Industry Leadership Roundtable discussion on ways to curb emissions of hydrofluorocarbons.